Hemanext has committed its resources to the continuing effort of the transfusion medicine community to save lives and improve patient outcomes. The company is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy.
View Investor Portal for confidential information and updates. Learn about Hemanext ONE technology.
New Investor? CLICK HERE to sign-up.
Hemanext Partners with the Miami Chapter of the Sickle Cell Disease Association of America to Support Local Sickle Cell Disease Community
Partnership Will Expand to Include Educational and Donation Event with OneBlood LEXINGTON, Mass.,...
Hemanext Announces Close of Series B Equity Funding Round
Raises $18 Million in New Equity Financing Appoints Healthcare Luminary Dr. Ismail Kola to Board...
European Patients Have Begun Receiving Transfusions with Hemanext ONE® RBC Processing and Storage System
LEXINGTON, Mass., September 7, 2022, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood...
Hemanext Announces Publication of Hypoxic Blood Storage Study in Blood Advances
Research shows that hypoxic storage preserves faster oxygen unloading from red blood cells...
Hot Topics in Transfusion Medicine
Research showing promise and opportunity for innovations in blood quality in the field of transfusion medicine.
Impact of the Age of Blood
Bruun-Rasmussen P, et al. Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data. Blood. 2022; doi: 10.1182/blood.2022015892.
A study at the University of Copenhagen investigated the adverse effects of the storage of red blood cell (RBC) units. This study was conducted using real-world data from a Danish blood transfusion database from 2008-2018, marginal structural models (MSM) to estimate the potential causal effect of transfusing RBC units with different storage durations, and a unique directed acyclic graph (DAG) of study assumptions used to suggest and adjust covariates for subsequent statistical modeling adjustment.
- Enrollment: 89,799 patients received more than 340,000 RBC transfusions met the eligibility criteria (chronic and massive transfusion recipients were excluded)
- Endpoints: An individual receiving >1-week old blood has a 2.44% higher chance of dying during a 28-day follow-up period than someone receiving < 1-week old blood and a 2.29% higher chance of dying or having a thromboembolic event during a 28-day follow-up period than someone receiving < 1-week old blood
This study suggests that transfusing exclusively older RBC units stored for >1 or 2 weeks increases the 28-day recipient mortality and risk of thromboembolism or death compared with transfusing fresher RBC units.
Curated resources for news, contact information, and newsletter sign-up.